TY - JOUR
AU - Rosen, Clifford J
AB - COMMENTARY J JBMR I never think of the future. It comes soon enough. relatively specific for bone, it makes an ideal target for —Albert Einstein, 1933 therapeutic intervention. Interestingly, unlike other antiresorp- tive drugs, odanacatib (ODN) inhibits matrix dissolution but does fter alendronate was approved for the treatment of not affect acid secretion nor the viability of the osteoclast. Apostmenopausal osteoporosis, expectations rose that new Whether this may prove advantageous for its eventual safety therapies would be developed to cure this debilitating disease. profile still needs to be determined. Early trials with the Public and private collaborations pushed the envelope to prototypical CatK inhibitors suffered from high expectations. discover ‘‘druggable’’ targets in the skeletal remodeling unit. Some investigators felt that the CatK inhibitors were both Initially, those efforts focused on the bone-resorbing osteoclast antiresorptive and anabolic. Unfortunately, there were signifi- and ultimately led to the approval of three bisphosphonates that cant side effects from these agents, particularly in the skin. differed not in their mode of action but rather in their frequency In the current article, Bone and colleagues confirm earlier work of administration. In contrast, the development and subsequent suggesting that the CatK enzyme may be a good 
TI - Exploiting new targets for old bones
JF - Journal of Bone and Mineral Research
DO - 10.1002/jbmr.91
DA - 2010-04-30
UR - https://www.deepdyve.com/lp/oxford-university-press/exploiting-new-targets-for-old-bones-GG9v3b4Iqu
SP - 934
EP - 936
VL - 25
IS - 5
DP - DeepDyve
ER -